Heidelberger, Pleven, and Duschinsky and associates in 1957 specifically designed 5-fluorouracil as an antimetabolite for cancer chemotherapy.1,2 Beneficial effects of 5-fluorouracil on experimental animal cancers were obtained.3 Subsequent clinical trials have indicated the efficacy of 5-fluorouracil (5-FU) in treatment of hepatoma, cancer of colon, rectum, and breast.
Murphy6 and Wolman7 have reported the use of 5-fluoro2#x2032;-deoxyuridine in the treatment of leukemia and neoplasms of childhood. Ansfield8 has noted that the 5-FU compounds produce less toxicity in children than in adults.
This clinical study is a report of 16 children who have received 5-FU for advanced or disseminated malignancies. The disappearance and reduction in size of malignancies following 5-FU have been remarkable. Complete regression of tumor has been noted in one patient with sarcoma of the larynx and in one patient with lymphosarcoma of the abdomen.
Methods and Materials
All the patients treated in this series had the diagnosis